Floatz logo

Sargramostim

Neoplasms

Partner Therapeutics, Inc.protein_peptidePhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

118 Active assets in the Neoplasms cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
Feladilimab
GlaxoSmithKline
Phase 2BB
Carboplatin
Bristol-Myers Squibb
Phase 3BB
Cetuximab
Mirati Therapeutics Inc.
Phase 4B
PREDNISONE TABLETS
The First Affiliated Hospital of Soochow University
Phase 3B

View all 50 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →